ELAB - PMGC Holdings Inc.


1.01
-0.130   -12.871%

Share volume: 191,459
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%

$1.14
-0.13
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
40%
Profitability 35%
Dept financing 25%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
-15.13%
1 Month
-49.75%
3 Months
-79.72%
6 Months
-76.83%
1 Year
-15.83%
2 Year
34.13%
Key data
Stock price
$1.01
P/E Ratio 
0.00
DAY RANGE
$1.01 - $1.12
EPS 
-$24.54
52 WEEK RANGE
$0.63 - $11.13
52 WEEK CHANGE
-$17.89
MARKET CAP 
3.936 M
YIELD 
N/A
SHARES OUTSTANDING 
744.121 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-10-2025
NEXT EARNINGS DATE
N/A
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$195,625
AVERAGE 30 VOLUME 
$2,802,770
Company detail
CEO: Jordan R. Plews
Region: US
Website: elevailabs.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a physician-dispensed skincare company with a focus on modernizing aesthetic skincare. Elevai Labs, Inc. was incorporated in Delaware in June 2020 under the original name Reactive Medical Labs Inc. Upon completion of the stock transfer agreement, Reactive Medical Inc. became our wholly owned subsidiary. In September 2022, Reactive Medical Inc. changed its name to Elevai Research Inc. Our principal executive offices are located at 120 Newport Center Dr. #250, Newport Beach, CA 92660. As of the date of this prospectus, we are qualified to do business as a foreign corporation in the state of California. Our telephone number is 866-794-4940. Our website address is www.elevailabs.com.

Recent news